CA2002182C - Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use - Google Patents
Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use Download PDFInfo
- Publication number
- CA2002182C CA2002182C CA 2002182 CA2002182A CA2002182C CA 2002182 C CA2002182 C CA 2002182C CA 2002182 CA2002182 CA 2002182 CA 2002182 A CA2002182 A CA 2002182A CA 2002182 C CA2002182 C CA 2002182C
- Authority
- CA
- Canada
- Prior art keywords
- serotonin
- drug
- drugs
- fenfluramine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions useful in the treatment of disturbances of appetite, disturbances of mood, or both, associated with premenstrual syndrome; as well as methods of use therefor. The compositions include serotoninergic drugs, such as d-fenfluramine and fluoxetine.
Description
TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME
Description Background Each month, for a few days prior to the onset 05 of menstruation, many millions of otherwise-healthy American women develop symptoms of disturbed mood and appetite that can be strikingly similar to those reported by,patients with Seasonal Affective Disorder (SAD), carbohydrate-craving obesity, or -the non-anorexic variants of bulimia. This syndrome was first termed "premenstrual tension" by R. T. Frank in 1931 and' is a very common phenomenon. According .
to Guy Abraham of UCLA, "...of every ten patients to walk into a,gynecologist's affice, three or four will suffer from premenstrual tensipn...", and in some the symptoms will be of such severity as to include attempts at suicide. Current Progress in Obstetrics and Gynecalog~, 3:5-39 (1980) Initial descriptions of the Premenstrual Syndrome (PMS) focused on its association with "nervous tension", headache; and weight gain. The weight gain observed was initially attributed to excessive retention of salt and Taater, which does indeed occur in some PMS patients: However,'it soon became evident that it..was also a consequence of the widespread tendency of PMS individuals to crave and overconsume carbohydrates; particularly foods with a sweet taste. PMS is also now referred to as late
Description Background Each month, for a few days prior to the onset 05 of menstruation, many millions of otherwise-healthy American women develop symptoms of disturbed mood and appetite that can be strikingly similar to those reported by,patients with Seasonal Affective Disorder (SAD), carbohydrate-craving obesity, or -the non-anorexic variants of bulimia. This syndrome was first termed "premenstrual tension" by R. T. Frank in 1931 and' is a very common phenomenon. According .
to Guy Abraham of UCLA, "...of every ten patients to walk into a,gynecologist's affice, three or four will suffer from premenstrual tensipn...", and in some the symptoms will be of such severity as to include attempts at suicide. Current Progress in Obstetrics and Gynecalog~, 3:5-39 (1980) Initial descriptions of the Premenstrual Syndrome (PMS) focused on its association with "nervous tension", headache; and weight gain. The weight gain observed was initially attributed to excessive retention of salt and Taater, which does indeed occur in some PMS patients: However,'it soon became evident that it..was also a consequence of the widespread tendency of PMS individuals to crave and overconsume carbohydrates; particularly foods with a sweet taste. PMS is also now referred to as late
-2-luteal phase syndrome. D.N.S. III, Revised, American Psychiatric Association (1987).
There have. been numerous suggestions made about the etiology of PMS. For example, some hypothesized 05 that it was caused by a uterine toxin. Others suggested its cause was overconsumption of sweets, which was presumably followed by excessive insulin secretion, hypoglycemia, and inadequate brain glucose and resulted in the often observed depres-lion and anxiety. It has also been postulated that the behavioral symptoms result from the tissue edema often observed and that the psychological changes result from feelings of loss or the social complex-ities generated by the discomforts of menstruation.
However, none of these theories has been substantiated: PMS can persist after hysterectomy and, hence, uterine toxins cannot be its cause; the hyperinsulinism of PMS is not associated with low blood glucose levels, and is probably the con-sequence of a behavioral aberration (i.e., the tendency of premenstrual women to choose high-carbohydrate diets, which potentiate insulin secre-tion)--rather than the cause; the moodwand ap-petitive changes of PMS are poorly correlated with the tissue swelling; and subhuman primates who are presumably exempt from the psychodynamic or social complexities of human life, also exhibit character-istic behavioral changes premenstrually.
There have been many treatments suggested for 3p overcoming-or reducing the symptoms of PMS. These
There have. been numerous suggestions made about the etiology of PMS. For example, some hypothesized 05 that it was caused by a uterine toxin. Others suggested its cause was overconsumption of sweets, which was presumably followed by excessive insulin secretion, hypoglycemia, and inadequate brain glucose and resulted in the often observed depres-lion and anxiety. It has also been postulated that the behavioral symptoms result from the tissue edema often observed and that the psychological changes result from feelings of loss or the social complex-ities generated by the discomforts of menstruation.
However, none of these theories has been substantiated: PMS can persist after hysterectomy and, hence, uterine toxins cannot be its cause; the hyperinsulinism of PMS is not associated with low blood glucose levels, and is probably the con-sequence of a behavioral aberration (i.e., the tendency of premenstrual women to choose high-carbohydrate diets, which potentiate insulin secre-tion)--rather than the cause; the moodwand ap-petitive changes of PMS are poorly correlated with the tissue swelling; and subhuman primates who are presumably exempt from the psychodynamic or social complexities of human life, also exhibit character-istic behavioral changes premenstrually.
There have been many treatments suggested for 3p overcoming-or reducing the symptoms of PMS. These
-3-include carbohydrate-free diets, vitamin supple-ments, ovarian hormones, detoxifying agents, ir-radiation of the ovaries and pituitary, and use of diuretics. These approaches have all had limited 05 success, however, and a means of treating the mood and appetite disturbances commonly experienced on a recurring basis by a large number of women would be of great benefit.
Summary of the Invention The present invention is based on the discovery that administration of an agent which selectively enhances sero~tonin-mediated neurotransmission is useful in the treatment of disturbances of mood (e. g., depression, anxiety) and of appetite (e. g., carbohydrate craving, weight gain) commonly associated with the premenstrual Syndrome (PMS).
Agents or drugs useful in enhancing serotonin-~r,ediated neurotransmission, or the effect of serotonin within the brain synapses, are ref2rr~d'to as serotoninergic drugs and include 1) drugs which act to increase the quantity of serotonin present within the synapses and 2) drugs which act to enhance the effects of serotonzn present with brain syna~ses, generally by activating post-synaptic serotonin receptors.
Drugs which act to increase the quantity of serotonin with~.n brain synapses include those which act to increase serotonin production, cause its release, or suppress its reup~ake; those which block
Summary of the Invention The present invention is based on the discovery that administration of an agent which selectively enhances sero~tonin-mediated neurotransmission is useful in the treatment of disturbances of mood (e. g., depression, anxiety) and of appetite (e. g., carbohydrate craving, weight gain) commonly associated with the premenstrual Syndrome (PMS).
Agents or drugs useful in enhancing serotonin-~r,ediated neurotransmission, or the effect of serotonin within the brain synapses, are ref2rr~d'to as serotoninergic drugs and include 1) drugs which act to increase the quantity of serotonin present within the synapses and 2) drugs which act to enhance the effects of serotonzn present with brain syna~ses, generally by activating post-synaptic serotonin receptors.
Drugs which act to increase the quantity of serotonin with~.n brain synapses include those which act to increase serotonin production, cause its release, or suppress its reup~ake; those which block
-4-presynaptic receptorst and those which block the activity of monoamine oxidase. Related drugs, the serotonin agonists, share with these drugs the ability to enhance serotonin-mediated neuro-05 transmission.
One or more of these serotoninergic drugs can be administered to an individual in an amount effective to reduce or prevent the mood and/or appetite disturbances which would otherwise be observed in the individual prior to onset of men-struation. The drug (or drugs) can be administered, for example, orally, by subcutaneous, or other injection-, intravenously, parenterally, trans-dermally; or rectally and can be given in various forms, such as a powder, tablet, capsule, solution or emulsion. In these various dorms, the sero-toninergic drug or drugs can be combined with additional substances, such as those needed to serve as fillers, diluents, binders, flavorings or color-ing agents or coating materials.
The length of time during which a serotonin-ergic drug or drugs will be given varies on an individual basis, but will generally begin 1 to 14 days prior to menstruation and may continue for several days (e. g., 3 days) after onset. of men-struation.
In one'embodiment of the present invention, d-fenfluramine, or d,l-fenfluramine, which act to release serotonin and inhibit its inactivation by reuptake, is administered to an individual, prior to
One or more of these serotoninergic drugs can be administered to an individual in an amount effective to reduce or prevent the mood and/or appetite disturbances which would otherwise be observed in the individual prior to onset of men-struation. The drug (or drugs) can be administered, for example, orally, by subcutaneous, or other injection-, intravenously, parenterally, trans-dermally; or rectally and can be given in various forms, such as a powder, tablet, capsule, solution or emulsion. In these various dorms, the sero-toninergic drug or drugs can be combined with additional substances, such as those needed to serve as fillers, diluents, binders, flavorings or color-ing agents or coating materials.
The length of time during which a serotonin-ergic drug or drugs will be given varies on an individual basis, but will generally begin 1 to 14 days prior to menstruation and may continue for several days (e. g., 3 days) after onset. of men-struation.
In one'embodiment of the present invention, d-fenfluramine, or d,l-fenfluramine, which act to release serotonin and inhibit its inactivation by reuptake, is administered to an individual, prior to
-5-the onset of her menstrual period, in a quantity sufficient to ameliorate or prevent the mood dis-turbances and/or to suppress the weight gain and the increased appetite which otherwise would be evident.
05 In a further embodiment, fluoxetine, which acts to inhibit reuptake of serotonin, is administered in a quan~.ity sufficient to suppress these effects.
Administration of a serotoninergic drug accord-ing to the method of the present invention is of l0 great benefit to women who experience disturbances of mood and/or appetite prinr,to onset of their menstrual period because the drug or drugs admini-stered act to alleviate or prevent such adverse premenstrual~symptoms.
15 Detailed Description of the Invention The present invention relates to compositions useful in alleviating or preventing disturbances of mood and/or appetite which occur prior to onset of menstruation; as well as ~o methods of their use in 20 treating such disturbances. Such compositions include one or more serotoninergic agents ordrugs (i.a., one or more agents or drugs which selectively enhance serotonin-mediated neurotransmission).
Serotoninergic drugs included in compositions 25of the present invention act to enhance serotonin-mediated neurotransmission by increasing the,quan-tity of serotonin present within brain synapses, by activating post-synaptic serotonin receptors, or both. One 'or more of such serotoninergic drugs may be present in a composition of the present invention and may be present alone (i.e., only serotoninergic drug(s)) or in combination with other substances which function in another capacity (e.g., as a 05 filler, binder, etc.), as described below.
The neurotransmitter serotonin (5-hydroxytryp-tamine or 5-HT)Yis 3-(beta-aminoethyl)-5-hydroxyin-dole. 2t stimulates or inhibits a variety of smooth muscles and nerves and, among others, has effects on secretion by both exocrine and endocrine glands and on functioning of the respiratory, cardiovascular and central nervous systems. Within the central nervous system (CNS), serotonimserves as a neuro-transmitter in the brain and spival cord, where it l5 is the chemical transmitter of neurons referred to as tryptaminergic or serotoninergia neurons. These neurons are involved in control of sleep, appetite, nutrient selection, blood pressure; mood, endocrine secretion, aggressivity and numerous other sensitiv-ities to external stimuli.
Numerous substances or drubs have been shown to affect serotonin activity. For example, endogenous serotonin levels can be increased by administering _ tryptophan, the precursor of sero~t~nin: Fernstrom, ~'~' and Wurtman; R.J., Science, 173:1~I9-152 (1971).
It has now been discovered that adr~tinistration of an agent or a drug which selectively enhances serotonin-mediated neurotransmission suppresses the weight gain and the increased appetite; part2cularly for carbohydrates, as well as decreasing the depression and other negative mood states, which many women experience prior to onset of menstruation. An agent or a drug which selectively enhances serotoninmediated neurotransmission has 05 been shown to be particularly effective in having these effects.
Administration of a drug (or drugs) which enhances serotonin-mediated neurotransmission by increasing the quantity of serotonin caithin brain synapses or by activating post-synaptic serotonin .
receptors results in amelioration or elimination of these commonly-experienced adverse effects.
For example, it has been shoran that adminis-tration of d-fenfluramine (an anorectic drug) to women prior to onset of their menstrual period results in a decrease in depression and other negative mood states.(e.g., tension, anger, con-fusion, irritability), as assessed using recogni2ed tests (see Example 1) and,in lower consumption of high-carbohydrate foods than observed when they were not given the drug (i:.a.; were given a placebo). A
d-fenfluramine analogue, d,'1-fenfluramine, has the same effect.
Similarly, administration of fluoxetine, which suppresses reuptake of serotonin and, thus, in-creases the quantity of-serotonin available at brain synapses, has been shown to ameliorate the depressed moods and carbohydrate craving othercaise seen in subjects prior to their menstrual period. In addition, it was effective in suppressing the weight _g_ gain usually associated with the premenstrual phase in the subjects studied.
In place of, ar in addition to, d-fenfluramine, d,l-fenfluramine and fluaxetine, other drugs which 05 have the effect of enhancing serotonin-mediated neurotransmission can be administered. For example, the quantity of serotonin present at a given time or over a period of time can be enhanced by admini-stering a drug which has any o.f the follo:aing effects:
1. increases serotonin production (e. g., tryptophan lithium);
2. causes serotonin release, e.g., d-fenfluramine, d,l-fenfluramine chlorimipramine (also known as ~clomipromine);
3. suppresses serotonin reuptake; e.g., fluoxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591, LM5008, sertraline or 1S-4S-N-methyl-4-(3,4 dichlorophenyl)-1,2,3,4,-tetrahydro-1-naphthylamine, paroxetine, DU 24565, indalpzne, CGP 6085/A, wY 25093, alaprociate, zimelidine, cyanimipramine; desyrel (trazodone hydrochloride) ar trazodone amitriptyline-or elavil (amitriptyline hydrochloride), imipramine or tofranil (imipramine hydrochloride); trimipramine or surmontil, doxepin or sinequan (doaepin hydrochloride), protriptyline or vivactil (protriptyline hydrochloride), nor-triptyline or aventyl (nortriptyline hydrochloride), dibenzoxazepine (also 05 known as amoxapine or asendin);
4. blocks .presynaptic receptors, e.g., metergoline, methysergide, cyproheptadine (which can also block postsynaptic receptors); or 5~ blocks monoamine oxidase, e.g., deprenyl, marplan or isocarboazide, nardil (phenelzine sulfate) or phenelzine, parnate (tranylcypromine sulfate) or tranylcypromine, furazalidone, procarbazine, moclobemide or aurorix, brofaromine).
The chemical names of DU 24565, CGP 6085/A, and ~dY
25093 are, respectively, 6-nitroquipazine, 4-(5,6-' dimethyl-2-benzofuranyl) pi.peridine HCl,.and 1-[1-([idol-3-yl]methyl) piperid-4-yl]-3-benzoylurea, respectively. Classen; K., et al.; NaunYn Schmiedeberqs Arch. Pharmacol., 326(3): 198°202 (1984); Kulakowski, E:C. et al., Clin. Exp. Hy~=
tens. [A); 7(4): 585-604 (1985): Di9gorY: G.L. et al., Areh. rnt: Pharacodyn. Ther., 248(1): 86-104 (1980) .
alternatively, serotonin-mediated neurotrans-mission can be enhanced by administering a drug, such as quipazine, m-CPP, MK212 or CP~I57493, which activates post~synaptic serotonin receptors:
In either case, such agents or drugs can be administered individually or in combination. The quantity of an individual drug to be administered will be determined on an individual basis and will 05 be .based at least in part on consideration of the individual's size., the severity of symptoms to be treated and the result sought.
The agents) or drugs) can be administered orally, by subcutaneous or other injection, l0 intravenously, parenterally, transdermally, or rectally. The form in which the drug caill be administered (e. g., powder, tablet, capsule, solution, emulsion) will depend on the route by, which it is administered.
15 The composition of the present invention can optionally include, in addition to the sero-toninergic drug,or drugs, other components. The components included in a particular composition are determined primarily by the manner in which the ' 20 composition is to be administered: For example, a composition to be administered orally in tablet form can include, in addition to ome or more sero-toninergic drugs, a filler (e. g.lactose); a binder (e. g:, carboxymethyl-cellulose, gum arabic; gel-25 atinj, an adjuvant, a flavoring agent, a coloring agent anda coating material (e.g, wax or'a pla -icizer): A composition to be administered or.allx, but in liquid form;' can include':one or more sero-toninergic drugs, and, optionally; an emulsifying agent, a flavoring anent and/or a'coloring agent.
In general, the composition of tk~e present invention is administered to an individual prior to the expected onset of her menstrual period. The length of time during which the drug (or drugs) is 05 administered varies on an individual basis, but in general will be from l to 14 days prior to onset of menstruation and might continue (e.g.,,3 days) after its onset. The dose of serotoninergic drug admini-stered daily will also vary on an individual basis ,10 and to some extent will be determined by the type and severity of symptoms to be treated. If the serotoninergic drug administered is d-fenfluramine or d;l-fenfluramine, a dose of from approximately 7 mg/day to approximately 60 mg/day is administered.
15 ~s described in Example I, a dose of 30 mg/day.of d-fenfluramine has been shown to lie effective ih .
decreasing depression and other negative mood states in 'subjects. In the case of fluoxetine admini-stration; a dose of from approximately 5 mg/day to 20 apps°ximately 120 mg/day is administered. ~s described in Example ILa dose of 40 mg/day, given on alternate days; has been shown to be effective in ameliorating the depressed mood and carbohydrate craving reported by ubjects not given fluoxetine.
25 It was also effective in suppressing the ~neight gain usually experienced. (See Example II): The sero-toninergic drug can be administered in a single close or in a number of smaller doses over a period oz time; for example; the 30 mg/day dose of d-fenfluramine can be administered in a series of smaller doses over the course of the day.
The present invention will now be illustrated by the following examples, which are not to be taken OS as limiting in any way.
Example I Assessment of effect of d-fenfluramine on Mood and Appetite Disturbances Associated with pMS
Seventeen women received either d-fenfluramine (30 mg/day) or a placebo for l5 days prior to their expected menstrual period. Each subject partici-pated in 6 randomized test'periods; in 3 of the test periods, each was given d-fenfluramine and in the other 3 test periods, was given a placebo. Mood was assessed 1-3 days before the onset of menses, using -the Hamilton Depression Scale and the PMS Symptom Rating Scale, for mood and appetite symptoms.
Hamilton, N., Journal of Neurosurgery and Psychiatry, 23;56-62 (1960); Steiner, M: et al., ACta Psychiatrica Scandinavia; 62:177-190 (1980).
Food intake was measured through the use of self-reports (when subjects were aut-patients), and directly (while subjects were inpatients), during one drug and'one placebo period; subjects also were weighed. As shown in Table 1; 15 of the 17 patients reported a decrease in depression and other negative mood states (such as°tensionanger, confusion,,and.
irritability) following drug treatment, but not following placebo treatment.
Effect of D-fenfluramine on PMS
Symptoms of Mood (Hamilton Depression Scale*) p5 Patient No. Placebo D-fenfluramine 3 12 . 2 14 t 6 g 17 10 9 17 9 ' 10 la 15 11 18 p Mean Score: 18 8 *Higher scpres on these tests indicate greater severity of symptoms. .
Lt was found that consumption of high carbo-hydrate foods increased for patients taking the placebo, but not for patients treated caith d-fenfluramine. Appetite and mood (meausured by the "PMS Symptoms Checklist" described by Steiner et al., ibid.) were assessed 1-3 days before the onset 0~ of menses. The results are shown in Table 2, cahich reflect mean scores for eleven of the seventeen women tested:
Effect of D-fenfluramine on PMS Svmptoms of Mood and Appetite Mood Scores Placebo D-fenfluramine mean score ' CMS Sympt. Checklist Mood 3a 0 Appetite a 1 Food Intake Calories 3300 1660 CHO(g)* 232, 130 Protein ~a d5 (Higher scores on these tes s indicate, greater severity, of symptoms) *CHO = carbohydrates Example II Assessment of Effect of Fluoxetine on Mood and Appetite Disturbance Associated ~~~ith FDIS
Fluoxetine (40 mg/day) was given on alternate days,' starting two caeeks prior to the expected onset 05 of a subject's menstrual period. Amelioration of the depressed mood and the carbohydrate cravings was reported (using the PPQS Symptom Rating Scale): ~~Iean scores for subjects taking the placebo were 36 and (for mood and appetite, respectively), and 9 and 10 3 for subjects taking fluoxetine. Fluoxetine also suppressed the usual weight gain associated with the premenstrual phase in these particular subjects.
Eauivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
05 In a further embodiment, fluoxetine, which acts to inhibit reuptake of serotonin, is administered in a quan~.ity sufficient to suppress these effects.
Administration of a serotoninergic drug accord-ing to the method of the present invention is of l0 great benefit to women who experience disturbances of mood and/or appetite prinr,to onset of their menstrual period because the drug or drugs admini-stered act to alleviate or prevent such adverse premenstrual~symptoms.
15 Detailed Description of the Invention The present invention relates to compositions useful in alleviating or preventing disturbances of mood and/or appetite which occur prior to onset of menstruation; as well as ~o methods of their use in 20 treating such disturbances. Such compositions include one or more serotoninergic agents ordrugs (i.a., one or more agents or drugs which selectively enhance serotonin-mediated neurotransmission).
Serotoninergic drugs included in compositions 25of the present invention act to enhance serotonin-mediated neurotransmission by increasing the,quan-tity of serotonin present within brain synapses, by activating post-synaptic serotonin receptors, or both. One 'or more of such serotoninergic drugs may be present in a composition of the present invention and may be present alone (i.e., only serotoninergic drug(s)) or in combination with other substances which function in another capacity (e.g., as a 05 filler, binder, etc.), as described below.
The neurotransmitter serotonin (5-hydroxytryp-tamine or 5-HT)Yis 3-(beta-aminoethyl)-5-hydroxyin-dole. 2t stimulates or inhibits a variety of smooth muscles and nerves and, among others, has effects on secretion by both exocrine and endocrine glands and on functioning of the respiratory, cardiovascular and central nervous systems. Within the central nervous system (CNS), serotonimserves as a neuro-transmitter in the brain and spival cord, where it l5 is the chemical transmitter of neurons referred to as tryptaminergic or serotoninergia neurons. These neurons are involved in control of sleep, appetite, nutrient selection, blood pressure; mood, endocrine secretion, aggressivity and numerous other sensitiv-ities to external stimuli.
Numerous substances or drubs have been shown to affect serotonin activity. For example, endogenous serotonin levels can be increased by administering _ tryptophan, the precursor of sero~t~nin: Fernstrom, ~'~' and Wurtman; R.J., Science, 173:1~I9-152 (1971).
It has now been discovered that adr~tinistration of an agent or a drug which selectively enhances serotonin-mediated neurotransmission suppresses the weight gain and the increased appetite; part2cularly for carbohydrates, as well as decreasing the depression and other negative mood states, which many women experience prior to onset of menstruation. An agent or a drug which selectively enhances serotoninmediated neurotransmission has 05 been shown to be particularly effective in having these effects.
Administration of a drug (or drugs) which enhances serotonin-mediated neurotransmission by increasing the quantity of serotonin caithin brain synapses or by activating post-synaptic serotonin .
receptors results in amelioration or elimination of these commonly-experienced adverse effects.
For example, it has been shoran that adminis-tration of d-fenfluramine (an anorectic drug) to women prior to onset of their menstrual period results in a decrease in depression and other negative mood states.(e.g., tension, anger, con-fusion, irritability), as assessed using recogni2ed tests (see Example 1) and,in lower consumption of high-carbohydrate foods than observed when they were not given the drug (i:.a.; were given a placebo). A
d-fenfluramine analogue, d,'1-fenfluramine, has the same effect.
Similarly, administration of fluoxetine, which suppresses reuptake of serotonin and, thus, in-creases the quantity of-serotonin available at brain synapses, has been shown to ameliorate the depressed moods and carbohydrate craving othercaise seen in subjects prior to their menstrual period. In addition, it was effective in suppressing the weight _g_ gain usually associated with the premenstrual phase in the subjects studied.
In place of, ar in addition to, d-fenfluramine, d,l-fenfluramine and fluaxetine, other drugs which 05 have the effect of enhancing serotonin-mediated neurotransmission can be administered. For example, the quantity of serotonin present at a given time or over a period of time can be enhanced by admini-stering a drug which has any o.f the follo:aing effects:
1. increases serotonin production (e. g., tryptophan lithium);
2. causes serotonin release, e.g., d-fenfluramine, d,l-fenfluramine chlorimipramine (also known as ~clomipromine);
3. suppresses serotonin reuptake; e.g., fluoxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591, LM5008, sertraline or 1S-4S-N-methyl-4-(3,4 dichlorophenyl)-1,2,3,4,-tetrahydro-1-naphthylamine, paroxetine, DU 24565, indalpzne, CGP 6085/A, wY 25093, alaprociate, zimelidine, cyanimipramine; desyrel (trazodone hydrochloride) ar trazodone amitriptyline-or elavil (amitriptyline hydrochloride), imipramine or tofranil (imipramine hydrochloride); trimipramine or surmontil, doxepin or sinequan (doaepin hydrochloride), protriptyline or vivactil (protriptyline hydrochloride), nor-triptyline or aventyl (nortriptyline hydrochloride), dibenzoxazepine (also 05 known as amoxapine or asendin);
4. blocks .presynaptic receptors, e.g., metergoline, methysergide, cyproheptadine (which can also block postsynaptic receptors); or 5~ blocks monoamine oxidase, e.g., deprenyl, marplan or isocarboazide, nardil (phenelzine sulfate) or phenelzine, parnate (tranylcypromine sulfate) or tranylcypromine, furazalidone, procarbazine, moclobemide or aurorix, brofaromine).
The chemical names of DU 24565, CGP 6085/A, and ~dY
25093 are, respectively, 6-nitroquipazine, 4-(5,6-' dimethyl-2-benzofuranyl) pi.peridine HCl,.and 1-[1-([idol-3-yl]methyl) piperid-4-yl]-3-benzoylurea, respectively. Classen; K., et al.; NaunYn Schmiedeberqs Arch. Pharmacol., 326(3): 198°202 (1984); Kulakowski, E:C. et al., Clin. Exp. Hy~=
tens. [A); 7(4): 585-604 (1985): Di9gorY: G.L. et al., Areh. rnt: Pharacodyn. Ther., 248(1): 86-104 (1980) .
alternatively, serotonin-mediated neurotrans-mission can be enhanced by administering a drug, such as quipazine, m-CPP, MK212 or CP~I57493, which activates post~synaptic serotonin receptors:
In either case, such agents or drugs can be administered individually or in combination. The quantity of an individual drug to be administered will be determined on an individual basis and will 05 be .based at least in part on consideration of the individual's size., the severity of symptoms to be treated and the result sought.
The agents) or drugs) can be administered orally, by subcutaneous or other injection, l0 intravenously, parenterally, transdermally, or rectally. The form in which the drug caill be administered (e. g., powder, tablet, capsule, solution, emulsion) will depend on the route by, which it is administered.
15 The composition of the present invention can optionally include, in addition to the sero-toninergic drug,or drugs, other components. The components included in a particular composition are determined primarily by the manner in which the ' 20 composition is to be administered: For example, a composition to be administered orally in tablet form can include, in addition to ome or more sero-toninergic drugs, a filler (e. g.lactose); a binder (e. g:, carboxymethyl-cellulose, gum arabic; gel-25 atinj, an adjuvant, a flavoring agent, a coloring agent anda coating material (e.g, wax or'a pla -icizer): A composition to be administered or.allx, but in liquid form;' can include':one or more sero-toninergic drugs, and, optionally; an emulsifying agent, a flavoring anent and/or a'coloring agent.
In general, the composition of tk~e present invention is administered to an individual prior to the expected onset of her menstrual period. The length of time during which the drug (or drugs) is 05 administered varies on an individual basis, but in general will be from l to 14 days prior to onset of menstruation and might continue (e.g.,,3 days) after its onset. The dose of serotoninergic drug admini-stered daily will also vary on an individual basis ,10 and to some extent will be determined by the type and severity of symptoms to be treated. If the serotoninergic drug administered is d-fenfluramine or d;l-fenfluramine, a dose of from approximately 7 mg/day to approximately 60 mg/day is administered.
15 ~s described in Example I, a dose of 30 mg/day.of d-fenfluramine has been shown to lie effective ih .
decreasing depression and other negative mood states in 'subjects. In the case of fluoxetine admini-stration; a dose of from approximately 5 mg/day to 20 apps°ximately 120 mg/day is administered. ~s described in Example ILa dose of 40 mg/day, given on alternate days; has been shown to be effective in ameliorating the depressed mood and carbohydrate craving reported by ubjects not given fluoxetine.
25 It was also effective in suppressing the ~neight gain usually experienced. (See Example II): The sero-toninergic drug can be administered in a single close or in a number of smaller doses over a period oz time; for example; the 30 mg/day dose of d-fenfluramine can be administered in a series of smaller doses over the course of the day.
The present invention will now be illustrated by the following examples, which are not to be taken OS as limiting in any way.
Example I Assessment of effect of d-fenfluramine on Mood and Appetite Disturbances Associated with pMS
Seventeen women received either d-fenfluramine (30 mg/day) or a placebo for l5 days prior to their expected menstrual period. Each subject partici-pated in 6 randomized test'periods; in 3 of the test periods, each was given d-fenfluramine and in the other 3 test periods, was given a placebo. Mood was assessed 1-3 days before the onset of menses, using -the Hamilton Depression Scale and the PMS Symptom Rating Scale, for mood and appetite symptoms.
Hamilton, N., Journal of Neurosurgery and Psychiatry, 23;56-62 (1960); Steiner, M: et al., ACta Psychiatrica Scandinavia; 62:177-190 (1980).
Food intake was measured through the use of self-reports (when subjects were aut-patients), and directly (while subjects were inpatients), during one drug and'one placebo period; subjects also were weighed. As shown in Table 1; 15 of the 17 patients reported a decrease in depression and other negative mood states (such as°tensionanger, confusion,,and.
irritability) following drug treatment, but not following placebo treatment.
Effect of D-fenfluramine on PMS
Symptoms of Mood (Hamilton Depression Scale*) p5 Patient No. Placebo D-fenfluramine 3 12 . 2 14 t 6 g 17 10 9 17 9 ' 10 la 15 11 18 p Mean Score: 18 8 *Higher scpres on these tests indicate greater severity of symptoms. .
Lt was found that consumption of high carbo-hydrate foods increased for patients taking the placebo, but not for patients treated caith d-fenfluramine. Appetite and mood (meausured by the "PMS Symptoms Checklist" described by Steiner et al., ibid.) were assessed 1-3 days before the onset 0~ of menses. The results are shown in Table 2, cahich reflect mean scores for eleven of the seventeen women tested:
Effect of D-fenfluramine on PMS Svmptoms of Mood and Appetite Mood Scores Placebo D-fenfluramine mean score ' CMS Sympt. Checklist Mood 3a 0 Appetite a 1 Food Intake Calories 3300 1660 CHO(g)* 232, 130 Protein ~a d5 (Higher scores on these tes s indicate, greater severity, of symptoms) *CHO = carbohydrates Example II Assessment of Effect of Fluoxetine on Mood and Appetite Disturbance Associated ~~~ith FDIS
Fluoxetine (40 mg/day) was given on alternate days,' starting two caeeks prior to the expected onset 05 of a subject's menstrual period. Amelioration of the depressed mood and the carbohydrate cravings was reported (using the PPQS Symptom Rating Scale): ~~Iean scores for subjects taking the placebo were 36 and (for mood and appetite, respectively), and 9 and 10 3 for subjects taking fluoxetine. Fluoxetine also suppressed the usual weight gain associated with the premenstrual phase in these particular subjects.
Eauivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
Claims (17)
1. Use of one or more serotonin-mediated neurotransmission enhancing drugs for the manufacture of a medicament. for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome in women.
2. Use according to Claim 1 wherein the one or more drugs is selected from the group consisting of drugs which enhance serotonin-mediated neurotrans-mission by increasing the quantity of serotonin present within brain synapses;
drugs which enhance serotonin-mediated neuro-transmission by activating brain post-synaptic serotonin receptors; and drugs which enhance serotonin-mediated neurotransmission by increasing the quantity of serotonin present within brain synapses and by activating brain post-synaptic serotonin receptors.
drugs which enhance serotonin-mediated neuro-transmission by activating brain post-synaptic serotonin receptors; and drugs which enhance serotonin-mediated neurotransmission by increasing the quantity of serotonin present within brain synapses and by activating brain post-synaptic serotonin receptors.
3. Use according to Claim 1 wherein the one or more drugs is selected from the group consisting of drugs which increase serotonin production; drugs which cause serotonin release; drugs which suppress serotonin reuptake; drugs which block presynaptic serotonin receptors; and drugs which block monoamine oxidase.
4. Use according to Claim 1 wherein the one or more drugs is selected from the group consisting of tryptophan, lithium, d-fenfluramine, d,l-fenfluramine, chlorimi-pramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, metergoline, methysergide, cyproheptadine, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide, brofaromine quipazine, m-CCP, MK212 and CM57493.
5. Use of a. a drug which increases serotonin levels within brain synapses and a drug which causes serotonin release;
b. a drug which increases serotonin levels within brain synapses and a drug which blocks serotonin reuptake;
c. a drug which increases serotonin levels within brain synapses and a drug which blocks synaptic inhibition of serotonin release;
d. a drug which blocks serotonin reuptake and a drug which blocks presynaptic inhibition of serotonin release;
e. a drug which causes serotonin release and a drug which blocks serotonin reuptake; or f. a drug which causes serotonin release and a drug which blocks presynaptic inhibition of serotonin release; all for the manufacture of a medicament for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, in a woman having premenstrual syndrome.
b. a drug which increases serotonin levels within brain synapses and a drug which blocks serotonin reuptake;
c. a drug which increases serotonin levels within brain synapses and a drug which blocks synaptic inhibition of serotonin release;
d. a drug which blocks serotonin reuptake and a drug which blocks presynaptic inhibition of serotonin release;
e. a drug which causes serotonin release and a drug which blocks serotonin reuptake; or f. a drug which causes serotonin release and a drug which blocks presynaptic inhibition of serotonin release; all for the manufacture of a medicament for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, in a woman having premenstrual syndrome.
6. Use of a. a drug selected from the group consisting of a monoamine oxidase inhibitor, lithium and tryptophan and a drug selected from the group consisting of d-fenfluramine, d,l-fenfluramine, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591 and LM5008, 1S-4S-N-methyl.-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline imipramine, trimipramine, doxepin, protiptyline, nortiptyline and dibenzoxazepine;
b. tryptophan and a drug selected from the group consisting of: metergoline, methysergide, cyproheptadine, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide and brofaromine;
c. a drug selected from the group consisting of fluoxetine, paroxetine, cyanimipramine, fluvoxamine, citalopram, femoxetine, ciano-pramine, ORG 6582, RU 25591, LM 5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indapline, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, and a drug selected from the group consisting of metergoline, methysergide, and cyproheptadine; or d. d-fenfluramine, d,l-fenfluramine or chlorimipramine and a drug selected from the group consisting of fluoxetine, fluvoxamine, citalopram, femoxetine, paroxetine, cianopramine, ORG 6582, RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone cyanimipramine, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, and dibenzoxazepine; all for the manufacture of a medicament for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, in a woman having premenstrual syndrome.
b. tryptophan and a drug selected from the group consisting of: metergoline, methysergide, cyproheptadine, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide and brofaromine;
c. a drug selected from the group consisting of fluoxetine, paroxetine, cyanimipramine, fluvoxamine, citalopram, femoxetine, ciano-pramine, ORG 6582, RU 25591, LM 5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indapline, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, and a drug selected from the group consisting of metergoline, methysergide, and cyproheptadine; or d. d-fenfluramine, d,l-fenfluramine or chlorimipramine and a drug selected from the group consisting of fluoxetine, fluvoxamine, citalopram, femoxetine, paroxetine, cianopramine, ORG 6582, RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone cyanimipramine, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, and dibenzoxazepine; all for the manufacture of a medicament for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, in a woman having premenstrual syndrome.
7. Use of at least two serotoninergic drugs for the manufacture of a medicament for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, in women.
8. Use according to Claim 7 wherein the serotoninergic drugs are selected from the group consisting of tryptophan, lithium, d-fenfluramine d,l-fenfluramine, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nor triptyline, dibenzoxazepine, metergoline, methysergide, cyproheptadine, quipazine, M-CCP, MK212, CM57493, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide and brofaromine.
9. A composition for administration to women for treating disturbances of mood, disturbances of appetite, or bath, associated with premenstrual syndrome, comprising at least two drugs which enhance serotonin-mediated neurotransmission.
10. A composition of Claim 9 wherein the drugs are selected from the group consisting of drugs which enhance serotonin-mediated neurotransmisson by increasing the quantity of serotonin present within brain synapses; drugs which enhance serotonin-mediated neurotransmission by activating brain post-synaptic serotonin receptors; and drugs which enhance serotonin-mediated neurotransmission by increasing the quantity of serotonin present within brain synapses and by activating brain post-synaptic serotonin receptors.
11. A composition of Claim 9 wherein the drugs are selected from the group consisting of drugs which increase serotonin production; drugs which cause serotonin release; drugs which suppress serotonin reuptake; drugs which block presynaptic serotonin receptors; and drugs which block monoamine oxidase.
2. A composition of Claim 9 wherein the drugs are selected from the group consisting of tryptophan, lithium, d-fenfluramine, d,l-fenfluramine, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU
25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU
24565, indalpine, CGP 6085,/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, meter-goline, methysergide, cyproheptadine, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide, brofaromine quipazine, m-CCP, MK212 and CM57493.
25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU
24565, indalpine, CGP 6085,/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, meter-goline, methysergide, cyproheptadine, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide, brofaromine quipazine, m-CCP, MK212 and CM57493.
13. A composition for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, in a woman having premenstrual syndrome, comprising:
a. a drug which increases serotonin levels within brain synapses and a drug which causes serotonin release;
b. a drug which increases serotonin levels within brain synapses and a drug which blocks serotonin reuptake;
c. a drug which increases serotonin levels within brain synapses and a drug which blocks synaptic inhibition of serotonin release;
d. a drug which blocks serotonin reuptake and a drug which blocks presynaptic inhibition of serotonin release;
e. a drug which causes serotonin release and a drug which blocks serotonin reuptake; or f. a drug which causes serotonin release and a drug which blocks presynaptic inhibition of serotonin release.
a. a drug which increases serotonin levels within brain synapses and a drug which causes serotonin release;
b. a drug which increases serotonin levels within brain synapses and a drug which blocks serotonin reuptake;
c. a drug which increases serotonin levels within brain synapses and a drug which blocks synaptic inhibition of serotonin release;
d. a drug which blocks serotonin reuptake and a drug which blocks presynaptic inhibition of serotonin release;
e. a drug which causes serotonin release and a drug which blocks serotonin reuptake; or f. a drug which causes serotonin release and a drug which blocks presynaptic inhibition of serotonin release.
14. A composition for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, in a woman having premenstrual :syndrome, comprising:
a. a drug selected from the group consisting of a monoamine oxidase inhibitor, lithium and tryptophan and a drug selected from the group consisting of d-fenfluramine, d,l-fenfluramine, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591 and LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline imipramine, trimipramine, doxepin, protiptyline, nortiptyline and dibenzoxazepine;
b. tryptophan and a drug selected from the group consisting of: metergoline, methysergide, cyproheptadine, deprenyl, isocarboazide, azide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide and brofaromine;
c. a drug selected from the group consisting of fluoxetine, paroxetine, cyanimipramine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591, LM 5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indapline, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, and a drug selected from the group consisting of metergoline, methysergide, and cyproheptadine; or d, d-fenfluramine, d,l-fenfluramine or chlorimipramine and a drug selected from the group consisting of fluoxetine, fluvoxamine, citalopram, femoxetine, paroxetine, cianopramine, ORG 6582, RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone cyanimipramine, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, and dibenzoxazepine.
a. a drug selected from the group consisting of a monoamine oxidase inhibitor, lithium and tryptophan and a drug selected from the group consisting of d-fenfluramine, d,l-fenfluramine, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591 and LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline imipramine, trimipramine, doxepin, protiptyline, nortiptyline and dibenzoxazepine;
b. tryptophan and a drug selected from the group consisting of: metergoline, methysergide, cyproheptadine, deprenyl, isocarboazide, azide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide and brofaromine;
c. a drug selected from the group consisting of fluoxetine, paroxetine, cyanimipramine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591, LM 5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indapline, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, and a drug selected from the group consisting of metergoline, methysergide, and cyproheptadine; or d, d-fenfluramine, d,l-fenfluramine or chlorimipramine and a drug selected from the group consisting of fluoxetine, fluvoxamine, citalopram, femoxetine, paroxetine, cianopramine, ORG 6582, RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone cyanimipramine, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, and dibenzoxazepine.
15. A composition for administration to women for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome, comprising at least two serotoninergic drugs.
16. A composition of Claim 15 wherein the serotoninergic drugs are selected from the group consisting of tryptophan, lithium, d-fenfluramine d,l-fenfluramine, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxetine, cianopramine, ORG 6582, RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP
6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nor triptyline, dibenzoxazepine, metergoline, methysergide, cyproheptadine, quipazine, M-CCP, MK212, CM57493, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide and brofaromine.
6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nor triptyline, dibenzoxazepine, metergoline, methysergide, cyproheptadine, quipazine, M-CCP, MK212, CM57493, deprenyl, isocarboazide, phenelzine, tranylcypromine, furazolidone, procarbazine, moclobemide and brofaromine.
17. Use of a drug which selectively enhances serotoninmediated neurotransmission for treating disturbances of mood, disturbances of appetite, or both, associated with premenstrual syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2002182 CA2002182C (en) | 1989-11-03 | 1989-11-03 | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2002182 CA2002182C (en) | 1989-11-03 | 1989-11-03 | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2002182A1 CA2002182A1 (en) | 1991-05-03 |
| CA2002182C true CA2002182C (en) | 2000-06-13 |
Family
ID=4143458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2002182 Expired - Fee Related CA2002182C (en) | 1989-11-03 | 1989-11-03 | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2002182C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759346B2 (en) | 2005-12-16 | 2014-06-24 | Novartis Ag | Organic compounds |
| US8933090B2 (en) | 2004-06-18 | 2015-01-13 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US9012451B2 (en) | 2002-09-04 | 2015-04-21 | Novartis Ag | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists |
| US9657010B2 (en) | 2004-07-14 | 2017-05-23 | Novartis Ag | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
-
1989
- 1989-11-03 CA CA 2002182 patent/CA2002182C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012451B2 (en) | 2002-09-04 | 2015-04-21 | Novartis Ag | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists |
| US9567343B2 (en) | 2002-09-04 | 2017-02-14 | Novartis Ag | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists |
| US9849117B2 (en) | 2002-09-04 | 2017-12-26 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| US8933090B2 (en) | 2004-06-18 | 2015-01-13 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US9475811B2 (en) | 2004-06-18 | 2016-10-25 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US9657010B2 (en) | 2004-07-14 | 2017-05-23 | Novartis Ag | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators |
| US8759346B2 (en) | 2005-12-16 | 2014-06-24 | Novartis Ag | Organic compounds |
| US9206181B2 (en) | 2005-12-16 | 2015-12-08 | Novartis Ag | 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2002182A1 (en) | 1991-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weiser et al. | The pharmacologic approach to the treatment of obesity | |
| US5708035A (en) | Methods of use and compositions of R(-) fluoxetine | |
| US5916923A (en) | Venlafaxine for the treatment of generalized anxiety disorder | |
| EP0386117B1 (en) | Treating premenstrual or late luteal phase syndrome | |
| US4971998A (en) | Methods for treating the premenstrual or late luteal phase syndrome | |
| EA011094B1 (en) | Highly-selective norepinephrine reuptake inhibitors, and methods of using the same | |
| US8481599B2 (en) | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism | |
| JP5491475B2 (en) | Treatment of mental conditions using muscarinic receptor M1 antagonists | |
| JP2019522666A (en) | Combination of adrenergic receptor agonists for the treatment of type 2 diabetes | |
| WO2001034172A2 (en) | Methods and compositions for treating reward deficiency syndrome | |
| US5223540A (en) | Method for treating the premenstrual or late luteal phase syndrome | |
| CA2002182C (en) | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use | |
| EP0792649A1 (en) | Treatment of sleep disorders | |
| IE912826A1 (en) | Method for treating the premenstrual or late luteal phase¹syndrome | |
| IE84082B1 (en) | Method for treating the premenstrual or late luteal phase syndrome | |
| Turner | Dexfenfluramine: its place in weight control | |
| US20050009927A1 (en) | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors | |
| JP2002514601A (en) | N. A. R. I. , Preferably a new drug combination of reboxetine and pindolol | |
| CA2591315C (en) | Method for treatment of depression and depressive mood disorders | |
| EP1667686A1 (en) | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors | |
| WO1992013452A1 (en) | Methods of use and compositions of r(-) fluoxetine | |
| TW574037B (en) | Nicotine addiction treatment | |
| Bolo | The Biological Basis of Bulimia | |
| MXPA00010945A (en) | New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol | |
| NZ555827A (en) | Use of an rauwolfia alkaloid such as reserpine for treating depression and depressive mood disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |